Posted by Michael Wonder on 16 Apr 2026
Opna Bio announces fast track designation granted to OPN-6602 for the treatment of multiple myeloma
15 April 2026 - Opna Bio today announced that the US FDA has granted fast track designation to OPN-6602, a dual EP300/CBP inhibitor, for the treatment of multiple myeloma.
The fast track designation applies to patients with relapsed/refractory multiple myeloma who have received at least four prior lines of therapy.
